These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11867010)

  • 1. Potential for immunotherapy in the treatment of herpesvirus infections.
    Bernstein DI
    Herpes; 2001 Mar; 8(1):8-11. PubMed ID: 11867010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
    Awasthi S; Hook LM; Shaw CE; Friedman HM
    Hum Vaccin Immunother; 2017 Dec; 13(12):2785-2793. PubMed ID: 28481687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylaxis and treatment of alpha herpesvirus infection--vaccine].
    Kimura H
    Nihon Rinsho; 2000 Apr; 58(4):928-32. PubMed ID: 10774218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
    Rose WA; Tuthill C; Pyles RB
    Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concept of immune-based therapies in chronic viral infections.
    Stanberry LR
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S1-5. PubMed ID: 8182508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Holy Grail: immune control of human herpes simplex virus infection and disease.
    Cunningham AL; Mikloska Z
    Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on short-course episodic and prevention therapies for herpes genitalis.
    Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
    Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory CpG treatment for genital HSV-2 infections.
    Herbst MM; Pyles RB
    J Antimicrob Chemother; 2003 Dec; 52(6):887-9. PubMed ID: 14585849
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
    Jones CA; Cunningham AL
    Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
    Stanberry LR; Burke R; Myers MG
    J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
    de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
    Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
    Wu JJ; Huang DB; Tyring SK
    Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon on systemic herpesvirus infections.
    Kern ER; Glasgow LA
    Tex Rep Biol Med; 1981-1982; 41():532-7. PubMed ID: 6189219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.